These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

296 related items for PubMed ID: 22335402

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier.
    Poller B, Wagenaar E, Tang SC, Schinkel AH.
    Mol Pharm; 2011 Apr 04; 8(2):571-82. PubMed ID: 21309545
    [Abstract] [Full Text] [Related]

  • 4. Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system.
    Sane R, Agarwal S, Mittapalli RK, Elmquist WF.
    J Pharmacol Exp Ther; 2013 Apr 04; 345(1):111-24. PubMed ID: 23397054
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP.
    de Vries NA, Buckle T, Zhao J, Beijnen JH, Schellens JH, van Tellingen O.
    Invest New Drugs; 2012 Apr 04; 30(2):443-9. PubMed ID: 20963470
    [Abstract] [Full Text] [Related]

  • 7. PET-CT imaging with [(18)F]-gefitinib to measure Abcb1a/1b (P-gp) and Abcg2 (Bcrp1) mediated drug-drug interactions at the murine blood-brain barrier.
    Vlaming ML, Läppchen T, Jansen HT, Kivits S, van Driel A, van de Steeg E, van der Hoorn JW, Sio CF, Steinbach OC, DeGroot J.
    Nucl Med Biol; 2015 Nov 04; 42(11):833-41. PubMed ID: 26264927
    [Abstract] [Full Text] [Related]

  • 8. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.
    Kodaira H, Kusuhara H, Ushiki J, Fuse E, Sugiyama Y.
    J Pharmacol Exp Ther; 2010 Jun 04; 333(3):788-96. PubMed ID: 20304939
    [Abstract] [Full Text] [Related]

  • 9. Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier.
    Cisternino S, Mercier C, Bourasset F, Roux F, Scherrmann JM.
    Cancer Res; 2004 May 01; 64(9):3296-301. PubMed ID: 15126373
    [Abstract] [Full Text] [Related]

  • 10. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice.
    Marchetti S, de Vries NA, Buckle T, Bolijn MJ, van Eijndhoven MA, Beijnen JH, Mazzanti R, van Tellingen O, Schellens JH.
    Mol Cancer Ther; 2008 Aug 01; 7(8):2280-7. PubMed ID: 18723475
    [Abstract] [Full Text] [Related]

  • 11. Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation.
    Lagas JS, van Waterschoot RA, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.
    Mol Cancer Ther; 2010 Feb 01; 9(2):319-26. PubMed ID: 20103600
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors.
    Minocha M, Khurana V, Qin B, Pal D, Mitra AK.
    Int J Pharm; 2012 Sep 15; 434(1-2):306-14. PubMed ID: 22633931
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1).
    Kort A, Durmus S, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.
    Pharm Res; 2015 Jul 15; 32(7):2205-16. PubMed ID: 25563977
    [Abstract] [Full Text] [Related]

  • 17. Dissimilar Effect of P-Glycoprotein and Breast Cancer Resistance Protein Inhibition on the Distribution of Erlotinib to the Retina and Brain in Humans and Mice.
    Biali ME, Auvity S, Cisternino S, Smirnova M, Hacker M, Zeitlinger M, Mairinger S, Tournier N, Bauer M, Langer O.
    Mol Pharm; 2023 Nov 06; 20(11):5877-5887. PubMed ID: 37883694
    [Abstract] [Full Text] [Related]

  • 18. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032).
    Mittapalli RK, Vaidhyanathan S, Sane R, Elmquist WF.
    J Pharmacol Exp Ther; 2012 Jul 06; 342(1):33-40. PubMed ID: 22454535
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan.
    de Vries NA, Zhao J, Kroon E, Buckle T, Beijnen JH, van Tellingen O.
    Clin Cancer Res; 2007 Nov 01; 13(21):6440-9. PubMed ID: 17975156
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.